A patient with neuro-Behçet's disease is successfully treated with etanercept: further evidence for the value of TNFalpha blockade

Behçet's disease is a chronic relapsing multisystem vasculitis with 49% of cases involving the CNS. Recently there have been two reports of neuro-Behçet's disease (NB) successfully treated with the tumour necrosis factor alpha (TNFalpha) monoclonal antibody infliximab. We describe a patien...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical neurology and neurosurgery 2007-04, Vol.109 (3), p.279-281
Hauptverfasser:	Alty, Jane E, Monaghan, Tanya M, Bamford, John M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Behcet Syndrome - drug therapy Behcet Syndrome - pathology Brain - pathology Etanercept Female Humans Immunoglobulin G - pharmacology Immunoglobulin G - therapeutic use Immunosuppressive Agents - pharmacology Immunosuppressive Agents - therapeutic use Magnetic Resonance Imaging Receptors, Tumor Necrosis Factor - therapeutic use Tumor Necrosis Factor-alpha - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Behçet's disease is a chronic relapsing multisystem vasculitis with 49% of cases involving the CNS. Recently there have been two reports of neuro-Behçet's disease (NB) successfully treated with the tumour necrosis factor alpha (TNFalpha) monoclonal antibody infliximab. We describe a patient with longstanding NB who was poorly responsive to azathioprine, cyclosporin, thalidomide and methotrexate. She showed a remarkable response when treated with the recombinant human TNFalpha receptor protein, etanercept. To the best of our knowledge this is the first report of NB successfully treated with etanercept.
ISSN:	0303-8467